{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-075198","form_type":"8-K","ticker":"ANVS","cik":"0001477845","company_name":"Annovis Bio, Inc.","filed_at":"2026-06-17T20:50:41+00:00","discovered_at":"2026-06-17T20:52:01.388678+00:00","generated_at":"2026-06-17T20:52:17.671335+00:00","sec_items":["5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Annovis Bio stockholders elect all five director nominees and approve all proposals at 2026 annual meeting","bullets":["All five director nominees elected; broker non-vote 12.55M shares abstained.","Ratification of Ernst & Young as auditors passed: 20.63M for, 568k against.","Equity plan amendment approved: share pool increased from 4M to 5.5M.","Say-on-pay advisory vote approved: 8.07M for, 901k against.","Advisory vote on frequency: 'Two Years' selected; Company will hold every two years."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-075198","json":"https://secwatch.observer/filing/0001104659-26-075198.json","markdown":"https://secwatch.observer/filing/0001104659-26-075198.md","text":"https://secwatch.observer/filing/0001104659-26-075198.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1477845/000110465926075198/0001104659-26-075198-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1477845/000110465926075198/tm2617993d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T20:52:17.671335+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"49c69b640dcfe85143fc0e5a220c1836cc85cf8d","claim":"Annovis Bio, Inc. shareholders approved Ratification of the Company's Independent Auditors at the 2026-06-17 meeting.","evidence_excerpt":"The ratification of the appointment of Ernst & Young LLP was approved by stockholders by the following vote: For Against Abstain 20,634,176 568,155 502,782","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1477845/000110465926075198/0001104659-26-075198-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"},{"claim_id":"a3461e95e9ac0de912cd34bb363315d75a910d91","claim":"Annovis Bio, Inc. shareholders approved Advisory (Non-Binding) Vote on the Compensation of the Company's Named Executive Officers at the 2026-06-17 meeting.","evidence_excerpt":"The compensation of the Company's named executive officers was approved b y the stockholders o n an advisory (non-binding basis), by the following vote: Broker Non-Vote For Against Abstain Broker Non-Vote 8,067,931 901,342 185,701 12,550,139","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1477845/000110465926075198/0001104659-26-075198-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"},{"claim_id":"ae25ee2c4ded5622992d646236b7e5b2f4320ca6","claim":"Annovis Bio, Inc. shareholders approved Election of Directors at the 2026-06-17 meeting.","evidence_excerpt":"Election of Directors All of the following five nominees were elected to the Company's Board of Directors, in accordance with the voting results listed below, to serve for a term of one year, until the next Annual Meeting and until their successors have been duly elected and have qualified.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1477845/000110465926075198/0001104659-26-075198-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"},{"claim_id":"c9e86c577a56642c1647095d67492e51eea8b67e","claim":"Annovis Bio, Inc. shareholders approved Amendment to the Annovis Bio, Inc. 2019 Equity Incentive Plan to increase the number of shares that may be issued under the Plan from 4,000,000 to 5,500,000 and to increase the maximum number of shares that may be awarded in any one year from 400,000 to 600,000 shares at the 2026-06-17 meeting.","evidence_excerpt":"The amendment to the Annovis Bio, Inc. 2019 Equity Incentive Plan to i ncrease the number of shares that may be issued under the Plan from 4,000,000 to 5,500,000 and to increase the maximum number of shares that may be awarded in any one year from 400,000 to 600,000 shares, was approved by stockholders by the following vote: For Against Abstain Broker Non-Vote 8,089,891 899,671 165,409 12,550,142","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1477845/000110465926075198/0001104659-26-075198-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}